Online inquiry

IVTScrip™ pSP6-VEE-mRNA-Anti-DLL4&VEGFA, ABT-165 Vector   (CAT#: GTVCR-WQ218MR)

This product GTVCR-WQ218MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the SP6 promoter to efficiently generate mRNA ecoding antibody which targeting DLL4&VEGFA . The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter SP6
Resistance Ampicillin
Species Humanized
RefSeq NM_019074.4; NM_001025366.3
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 54567; 7422
UniProt ID Q9NR61; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pSP6-VEE-mRNA-Anti-DLL4&VEGFA, ABT-165 Vector (GTVCR-WQ218MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ1974MR IVTScrip™ pSP6-VEE-mRNA-Anti-IL23A, MK-3222 Vector Vector MK-3222
GTVCR-WQ936MR IVTScrip™ pT7-VEE-mRNA-Anti-CD33, CDP-771 Vector Vector CDP-771
GTVCR-WQ449MR IVTScrip™ pSP6-VEE-mRNA-Anti-IL2RB, AMG 592 Vector Vector AMG 592
GTVCR-WQ1391MR IVTScrip™ pT7-VEE-mRNA-Anti-GLP1R, HM-12525A Vector Vector HM-12525A
GTVCR-WQ2122MR IVTScrip™ pSP6-VEE-mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5 Vector Vector OMP-18R5
GTVCR-WQ007MR IVTScrip™ pT7-VEE-mRNA-IL1A Vector Vector IL1A
GTVCR-WQ1351MR IVTScrip™ pT7-VEE-mRNA-Anti-CD33, h2H12ec Vector Vector h2H12ec
GTVCR-WQ1854MR IVTScrip™ pSP6-VEE-mRNA-Anti-EGFR&LGR5, MCLA-158 Vector Vector MCLA-158
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW